Adoptive Cell Therapy in Solid Tumors
Predictable Failure (And How to Avoid It) for Early-Stage Life Science Companies
In this webinar, Dr. Lucia Mokres breaks down the six major stakeholder categories relevant to most life science companies, and shares key strategies for closing the knowledge gap between founders and their market success.
Quality By Design: Remote Monitoring and eTMF Integration
Pullan’s Pieces Part III – A Business Development View of the Immunology Landscape
Must-Know Finance Concepts for Life Sciences Valuations - Part II
This webinar discusses which asset valuation methodology is most used by big pharma to evaluate possible partners or acquisitions and an explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital, and present value.
Essential Steps to Successful BioPharma Partnering
What's Hot & What's Not in Antibody Drug Conjugates Licensing
In this webinar, learn what targets are suitable, what are the trends in linkers and the drugs to be attached to the antibodies, how are companies dealing with the complexities of internalization and high cost of goods, what kind of data will drive an ADC licensing deal, how do the ADCs fit in the world of immuno-oncology and what is the future for ADCs.
Pullan’s Pieces II – A Business Development View of the Central Nervous System Landscape
Precision Medicine in Central Nervous System Drug Development
This webinar discusses lessons we can learn from the use of precision medicine in oncology, how has a recent clinical precision medicine application shown potential in the treatment of Alzheimer’s, what questions should you ask before you add a new biomarker to your clinical trial, the pros and cons of using biomarkers as surrogate endpoints.
From Founding to Exit: A Life Science Business Founder Perspective
Bispecifics in Oncology and Immuno Oncology
This webinar roundtable explores interesting technologies, the scientific issues, the clinical opportunities for developing multivalent biologics platforms, whether certain technologies, such as antibodies, their fragments, or non-antibody scaffolds, are superior to others, the pros and cons of such bispecifics for improving management of patients, and licensing and commercial strategies.